QPQuintin Pan

Quintin Pan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Quintin Pan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeted Disruption of Protein Kinase Cε Reduces Cell Invasion and Motility through Inactivation of RhoA and RhoC GTPases in Head and Neck Squamous Cell Carcinoma

    by Quintin Pan, Li Wei Bao, Theodoros N. Teknos, Sofia D. Merajver

    Over 70% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced stage III and IV disease. In spite of aggressive therapy, locoregional disease recurs in 60% and metastatic disease develops in 15% to 25% of patients causing a major decline in quality and length of life. Therefore, there is a need to identify and understand genes that are responsible for inducing an aggressive HNSCC phenotype. Evidence has shown that protein kinase C (PKC) ε is a transforming oncogene and may play a role in HNSCC progression. In this study, we determine the downstream signaling pathway mediated by PKCε to promote an aggressive HNSCC phenotype. RNA interference knockdown of PKCε in UMSCC11A and UMSCC36, two highly invasive and motile HNSCC cell lines with elevated endogenous PKCε levels, resulted in cells that were significantly less invasive and motile than the small interfering RNA–scrambled control transfectants; 51 ± 5% (P < 0.006) and 49 ± 3% (P < 0.010) inhibition in invasion and 69 ± 1% (P < 0.0005) and 66 ± 3% (P < 0.0001) inhibition in motility, respectively. PKCε-deficient UMSCC11A clones had reduced levels of active and serine-phosphorylated RhoA and RhoC. Moreover, constitutive active RhoA completely rescued the invasion and motility defect, whereas constitutive active RhoC completely rescued the invasion and partially rescued the motility defect of PKCε-deficient UMSCC11A clones. These results indicate that RhoA and RhoC are downstream of PKCε and critical for PKCε-mediated cell invasion and motility. Our study shows, for the first time, that PKCε is involved in a coordinated regulation of RhoA and RhoC activation, possibly through direct post-translational phosphorylation. (Cancer Res 2006; 66(19): 9379-84)


  • Open Access

    Protein Kinase Cε Is a Predictive Biomarker of Aggressive Breast Cancer and a Validated Target for RNA Interference Anticancer Therapy

    by Quintin Pan, Li Wei Bao, Celina G. Kleer, Michael S. Sabel, Kent A. Griffith, Theodoros N. Teknos, Sofia D. Merajver

    Tumor metastasis is the major cause of morbidity and mortality in patients with breast cancer. It is critical to identify metastasis enabling genes and understand how they are responsible for inducing specific aspects of the metastatic phenotype to allow for improved clinical detection and management. Protein kinase Cε (PKCε), a member of a family of serine/threonine protein kinases, is a transforming oncogene that has been reported to be involved in cell invasion and motility. In this study, we investigated the role of PKCε in breast cancer development and progression. High-density tissue microarray analysis showed that PKCε protein was detected in 73.6% (106 of 144) of primary tumors from invasive ductal breast cancer patients. Increasing PKCε staining intensity was associated with high histologic grade (P = 0.0206), positive Her2/neu receptor status (P = 0.0419), and negative estrogen (P = 0.0026) and progesterone receptor status (P = 0.0008). Kaplan-Meier analyses showed that PKCε was significantly associated with poorer disease-free and overall survival (log-rank, P = 0.0478 and P = 0.0414, respectively). RNA interference of PKCε in MDA-MB231 cells, an aggressive breast cancer cell line with elevated PKCε levels, resulted in a cell phenotype that was significantly less proliferative, invasive, and motile than the parental or the control RNA interference transfectants. Moreover, in vivo tumor growth of small interfering RNA-PKCε MDA-MB231 clones was retarded by a striking 87% (P < 0.05) and incidence of lung metastases was inhibited by 83% (P < 0.02). PKCε-deficient clones were found to have lower RhoC GTPase protein levels and activation. Taken together, these results revealed that PKCε plays a critical and causative role in promoting an aggressive metastatic breast cancer phenotype and as a target for anticancer therapy.